Skip to main content
Caplight Logo









Genezen

Genezen

Private
Indianapolis, IndianaHealthcare & Life Scienceshttps://www.genezen.com/

Last Round

Series C

Jul 1, 2024

Total Funding Raised

$18.5M

Company Overview

Genezen is a biotechnology company that provides contract development and manufacturing services for viral vectors used in cell and gene therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Biotech Equipment, Quality Management

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

contract development and manufacturing organizationCDMOviral vector manufacturingcell and gene therapycGMP manufacturinglentiviral vectorretroviral vectorbiomanufacturingprocess developmentfill and finishanalytical developmentbiotech outsourcingclinical stage manufacturingaseptic processing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genezen Comparables

Compare Genezen with similar companies based on industry and business-model similarity.

Genezen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VIVEbiotech
90%
ViroCell Biologics
88%
Andelyn Biosciences
87%

Genezen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJul 1, 2024
Growth EquityNov 2, 2023
Growth EquityJan 5, 2021

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 12, 2025

    Partnered with Humane Genomics for oncolytic virus therapy.

  • Nov 7, 2025

    Collaborating with Charlotte & Gwenyth Gray Foundation on CLN6 Batten Disease.

Recent news

Latest coverage and updates

  • has_revenueAug 10, 2026

    Genezen had revenue of $48M on Sep 1st '24.

  • is_developingAug 4, 2026

    Genezen Inc. is developing AAV9 gene replacement therapy for UBA5 disorder on Aug 4th '26.

  • partners_withAug 3, 2026

    Genezen Inc. partnered with Raiden Science on Aug 3rd '26.

Genezen Filings

Explore SEC and related filing metadata, where available.

Genezen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Genezen's valuation, stock price, and market status.

Is Genezen a public or private company?

Genezen is a private company.

What is the current stock price of Genezen?

Genezen is a private company with no public stock price. No recent secondary market data is available.

How much is Genezen worth (valuation)?

Valuation information for Genezen is not publicly available.

Can I buy Genezen stock?

Genezen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Genezen's last funding round?

Genezen's most recent funding round was Series C on July 1, 2024.

Who are the main investors in Genezen?

Investor information for Genezen is not publicly disclosed.

Will Genezen IPO soon?

No public IPO plans have been announced for Genezen.

How can I track Genezen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Genezen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIndianapolis, Indiana
Employee Range229
Year Founded2014
Last FundingJul 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?